<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37218538</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1610-0387</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG</Title><ISOAbbreviation>J Dtsch Dermatol Ges</ISOAbbreviation></Journal><ArticleTitle>Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis.</ArticleTitle><Pagination><StartPage>853</StartPage><EndPage>861</EndPage><MedlinePgn>853-861</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ddg.15114</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">The coronavirus SARS-CoV-2, which is the cause of COVID-19 disease in infected patients, has led to an ongoing worldwide pandemic. Although SARS-CoV-2 vaccination had a dramatic positive effect on the course of COVID-19, there has been increasing evidence of adverse effects after SARS-CoV-2 vaccination. This meta-analysis highlights the association between SARS-CoV-2 vaccination and de novo induction or aggravation of inflammatory and autoimmune skin diseases.</AbstractText><AbstractText Label="MATERIAL AND METHODS">A systematic meta-analysis of the literature on new onset or worsening of inflammatory and autoimmune diseases after SARS-CoV-2 vaccination was performed according to the PRISMA guidelines. The search strategy included following terms: "COVID-19/SARS-CoV-2 vaccine bullous pemphigoid/pemphigus vulgaris/systemic lupus erythematosus/dermatomyositis/lichen planus/leukocytoclastic vasculitis." Moreover, we describe representative cases from our dermatology department.</AbstractText><AbstractText Label="RESULTS">The database-search in MEDLINE identified 31 publications on bullous pemphigoid, 24 on pemphigus vulgaris, 65 on systemic lupus erythematosus, nine on dermatomyositis, 30 on lichen planus, and 37 on leukocytoclastic vasculitis until June 30th, 2022. Severity and response to treatment varied among the described cases.</AbstractText><AbstractText Label="CONCLUSIONS">Our meta-analysis highlights a link between SARS-CoV-2 vaccination and new onset or worsening of inflammatory and autoimmune skin diseases. Moreover, the extent of disease exacerbation has been exemplified by cases from our dermatological department.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley &amp; Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hinterseher</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Dermatology and Allergology, Philipps-University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hertl</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Dermatology and Allergology, Philipps-University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didona</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Dermatology and Allergology, Philipps-University Marburg, Marburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Dtsch Dermatol Ges</MedlineTA><NlmUniqueID>101164708</NlmUniqueID><ISSNLinking>1610-0379</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C535509">Erythema elevatum diutinum</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003882" MajorTopicYN="Y">Dermatomyositis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008010" MajorTopicYN="Y">Lichen Planus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010391" MajorTopicYN="Y">Pemphigoid, Bullous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010392" MajorTopicYN="Y">Pemphigus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37218538</ArticleId><ArticleId IdType="doi">10.1111/ddg.15114</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Park KS, Sun X, Aikins ME, et&#xa0;al. Non-viral COVID-19 vaccine delivery systems. Adv Drug Deliv Rev. 2021;169:137-151.</Citation></Reference><Reference><Citation>Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111-116.</Citation></Reference><Reference><Citation>Botton J, Dray-Spira R, Baricault B, et&#xa0;al. Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines. Vaccine. 2022;40:414-417.</Citation></Reference><Reference><Citation>Vanaparthy R, Mohan G, Vasireddy D, et&#xa0;al. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Infez Med. 2021;29:328-338.</Citation></Reference><Reference><Citation>Toussirot &#xc9;, Bereau M. Vaccination and Induction of Autoimmune Diseases. Inflamm Allergy Drug Targets. 2015;14:94-98.</Citation></Reference><Reference><Citation>Chen Y, Xu Z, Wang P, et&#xa0;al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165:386-401.</Citation></Reference><Reference><Citation>Sprow G, Afarideh M, Dan J, et&#xa0;al. Autoimmune skin disease exacerbations following COVID-19 vaccination. Front Immunol. 2022;13:899526.</Citation></Reference><Reference><Citation>Moro F, Fania L, Sinagra JLM, et&#xa0;al. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020;10.</Citation></Reference><Reference><Citation>Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res. 2018;310:95-106.</Citation></Reference><Reference><Citation>Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-&#x201c;vaccinosis&#x201d;: a dangerous liaison? J Autoimmun. 2000;14:1-10.</Citation></Reference><Reference><Citation>St&#xfc;bgen J-P. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev. 2014;13:31-39.</Citation></Reference><Reference><Citation>Crowe SR, Merrill JT, Vista ES, et&#xa0;al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Semin Arthritis Rheum. 2011;63:2396-2406.</Citation></Reference><Reference><Citation>Millet A, Decaux O, Perlat A, et&#xa0;al. Systemic lupus erythematosus and vaccination. Eur J Intern Med. 2009;20:236-241.</Citation></Reference><Reference><Citation>Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195-197.</Citation></Reference><Reference><Citation>Pardi N, Hogan MJ, Porter FW, et&#xa0;al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261-279.</Citation></Reference><Reference><Citation>Watad A, de Marco G, Mahajna H, et&#xa0;al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021;9.</Citation></Reference><Reference><Citation>McClatchy J, Yap T, Nirenberg A, et&#xa0;al. Fixed drug eruptions - the common and novel culprits since 2000. J Dtsch Dermatol Ges. 2022;20:1289-1302.</Citation></Reference><Reference><Citation>Ramot Y, Nanova K, Faitatziadou S-M, et&#xa0;al. Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2. J Dtsch Dermatol Ges. 2022;20:1123-1124.</Citation></Reference><Reference><Citation>Sagy I, Zeller L, Raviv Y, et&#xa0;al. New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review. Rheumatol Int. 2022;42:2261-2266.</Citation></Reference><Reference><Citation>Qian J, Xu H. COVID-19 Disease and dermatomyositis: A mini-review. Front Immunol. 2021;12:747116.</Citation></Reference><Reference><Citation>Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol. 2021;85:1274-1284.</Citation></Reference><Reference><Citation>Didona D, Hertl M. Paraneoplastische Autoimmundermatosen. Hautarzt. 2021;72:277-287.</Citation></Reference><Reference><Citation>Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021;41:509-518.</Citation></Reference><Reference><Citation>Mungmunpuntipantip R, Wiwanitkit V. Immunomodulatory systemic therapies in dermatology and response to COVID-19 vaccination. J Dtsch Dermatol Ges. 2022;20:357.</Citation></Reference><Reference><Citation>Didona D, Buhl T, Yazdi AS. Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology. J Dtsch Dermatol Ges. 2022;20:212-215.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>